| 产品详情 |
| Edit |   |
|---|
| Product Name | SDMA (Symmetric Dimethylarginine) ELISA |
|---|
| Description | The competitive SDMA (Symmetric Dimethylarginine) ELISA Kit uses the microtiter plate format. SDMA is bound to the solid phase of the microtiter plate. SDMA in the samples is acylated and competes with solid phase bound SDMA for a fixed number of rabbit anti-SDMA antiserum binding sites. When the system is in equilibrium, free Antigens and free Antigens-antiserum complexes are removed by washing. The antibody bound to the solid phase SDMA is detected by anti-rabbit / peroxidase. The substrate TMB / peroxidase reaction is monitored at 450 nm. The amount of antibody bound to the solid phase SDMA is inversely proportional to the SDMA concentration of the sample. Sample Types: serum, plasma. Range: 0.08 - 3.0 µmol/L. Sensitivity: 0.03 µmol/L. Time: 3 hours • Dosing of most drugs must be adapted in renal insufficiency, making accurate assessment of renal function an essential component of diagnostics in clinical medicine. Furthermore, even modest impairment of renal function has been recognized as a cardiovascular risk factor. As the most commonly used marker of renal excretory function, serum creatinine concentration, does not adequately respond to mild to moderate impairment of renal function, more sensitive markers for renal excretory function are urgently sought, especially in mild stages of renal impairment. SDMA is a methylated derivative of the amino acid L-arginine (symmetric dimethylarginine). SDMA is eliminated from the body exclusively by renal excretion; therefore SDMA plasma concentration is tightly related to renal function. Thus, quantification of plasma SDMA is an adequate means to assess renal function, as could be demonstrated in a series of recent clinical trials: In 18 clinical studies involving more than 2,100 samples systemic SDMA concentrations were highly correlated with inulin clearance as well as with various clearance estimates and better corresponded to mild renal function impairment than serum creatinine. Thus, SDMA exhibits properties of a reliable marker of renal function. Furthermore, there is evidence showing that elevated SDMA levels, as they may occur in renal function impairment, may prospectively indicate future risk of cardiovascular disease and mortality independently of the level of renal impairment. |
|---|
| Size | 1 x 96 well |
|---|
| Concentration | n/a |
|---|
| Applications | RUO |
|---|
| Other Names | SDMA, Symmetric Dimethylarginine, ADMA |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | SDM31-K01 |
|---|
| Price | |
|---|
| Order / More Info | SDMA (Symmetric Dimethylarginine) ELISA from EAGLE BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|